{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-26-000035","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2026-05-11T20:07:49+00:00","discovered_at":"2026-05-11T20:09:00.417903+00:00","generated_at":"2026-05-11T22:35:28.292559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"LENZ Therapeutics reports Q1 2026 net loss $41.5M, VIZZ product sales $1.7M","bullets":["Q1 2026 product sales $1.7M from ~25,000 paid prescriptions, 19% increase over Q4 2025.","Launched DTC campaign with Sarah Jessica Parker; website traffic up 10x; pilot TV advertising in April 2026.","Submitted MAA to EMA (March 2026) and MHRA (April 2026) for VIZZ; fourth ex-U.S. partnership with Lunatus in Jan 2026.","Net loss $41.5M ($1.32/share) vs. $14.6M ($0.53/share) in Q1 2025; cash $258.4M to fund operations to positive cash flow.","Sales force expanding from 88 to 117 by end of Q2 2026; launched ECP direct sales initiative in April 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-26-000035","json":"https://secwatch.observer/filing/0001815776-26-000035.json","markdown":"https://secwatch.observer/filing/0001815776-26-000035.md","text":"https://secwatch.observer/filing/0001815776-26-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577626000035/0001815776-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577626000035/lenz-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:35:28.292559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"101e6dd6959a075886b6b7f9b811a5d743b912f9","claim":"LENZ Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $41.5 million, EPS $1.32 per share (basic and diluted).","evidence_excerpt":"LENZ Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577626000035/0001815776-26-000035-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss for the three months ended March 31, 2026 was $41.5 million"},{"label":"EPS","value":"$1.32 per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}